Loading search results
RUNtoBBV
Sponsor study identifier
interventional
425
1 country
10
Study Start
October 25, 2018
Actual (reported)Primary Completion
October 22, 2019
Actual (reported)Study Completion
October 22, 2019
Actual (reported)Title Reaching out to the UNdiagnosed people infected with blood-borne viral infections (RUNtoBBV) Objectives 1. To study the efficacy of an outreach methodology to increase the uptake for screening, linkage to care and treatment in (active or former) people who use drugs (PWUD) Trial design Prospective multicenter interventional cohort design Number of subjects 336 inclusions (with prevalence of HCV Ab: 30%)
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 22, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 25, 2018
Actual (reported)October 22, 2019
Actual (reported)October 22, 2019
Actual (reported)January 7, 2020
Actual (reported)April 27, 2020
Actual (reported)HCV Ab+ (Hepatitis C Virus antibody)
test using whole capillary blood (finger prick testing)
day 1
HBsAg+ (Hepatitis B surface Antigen)
test using whole capillary blood (finger prick testing)
day 1
HIV Ab+ (human immunodeficiency virus) antibody
test using whole capillary blood (finger prick testing)
day 1
4. Questionnaire to Identify risk factors associated with the aforementioned blood borne viral infections (hepatitis C, hepatitis B and HIV)
day 1
Analysis of uptake of anti(retro)viral treatment
Day 1
Analysis of treatment adherence
up to one year
Analysis of treatment outcome
month 18
Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Free Clinic Antwerpen
Antwerp, 2000, Belgium
Free Clinic Antwerp
Antwerp, 2000, Belgium
ZNA Antwerp
Antwerp, 2000, Belgium
Ziekenhuis Oost-Limburg
Genk, 3600, Belgium
CAD Limburg
Hasselt, 3500, Belgium
Jessa Ziekenhuis
Hasselt, 3500, Belgium
Ziekenhuis Maas en Kempen
Maaseik, Belgium
Busschots D, Kremer C, Bielen R, Koc OM, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, Hens N, Mathei C, Robaeys G. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J. 2021 May 17;18(1):54. doi: 10.1186/s12954-021-00502-7.
Geert Robaeys, prof. dr.
Hasselt University
Rob Bielen, dr.
Hasselt University
425 participants (actual enrollment reported by the registry).
First Submitted
January 7, 2020
First Posted
April 27, 2020
Study Start
October 25, 2018
Actual (reported)Contact the study team to confirm eligibility.
Mariaziekenhuis Noord-limburg
Overpelt, 3900, Belgium
AZ Sint-Trudo
Sint-Truiden, 3800, Belgium
AZ Vesalius
Tongeren, 3700, Belgium
Primary Completion
October 22, 2019
Actual (reported)Study Completion
October 22, 2019
Actual (reported)Last Updated
April 29, 2020
Record last verified: 2020-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: